{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:52:00Z","timestamp":1783021920160,"version":"3.54.6"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"Importance<\/jats:title>Immune checkpoint inhibitors (ICIs) are recognized as revolutionary cancer therapies but have raised concerns about immune-related adverse events, including the development of autoimmune diseases.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the psoriasis risk associated with the use of ICIs in patients with cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This nationwide cohort study with a target trial emulation design used data from the Taiwan National Health Insurance database and the Taiwan Cancer Registry. The participants included were patients who received antineoplastic medications for cancer at stages III and IV between January 1, 2019, and June 30, 2021. Data were analyzed from May 2023 to July 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Patients treated with ICIs were classified as ICI users, while those who received chemotherapy or targeted therapies were categorized as non-ICI users.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The primary outcome was the incidence of psoriasis during the follow-up period. Stabilized inverse probability of treatment weighting (IPTW) was used to mitigate potential confounders. Cox and Fine-Gray hazard models were used to calculate hazard ratios (HRs) for psoriasis risk between groups.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 135\u202f230 patients who received antineoplastic medications (mean [SD] age, 62.94 [13.01] years; 45.1% female), 3188 patients were eligible for the ICI user group, while 132\u202f042 patients were eligible for the non-ICI user group. ICI users experienced a higher incidence of psoriasis at 5.76 cases per 1000 person-years, compared to 1.44 cases in the non-ICI group. After adjusting for demographics and comorbidities, ICI users were found to have a 2-fold increase in the risk of developing psoriasis (IPTW-adjusted HR, 3.31; IPTW-adjusted subdistribution HR, 2.43). Both as-started design and on-treatment design showed consistent findings, and the results were consistent and robust across all follow-up intervals and all sensitivity analyses.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, patients with cancer treated with ICIs faced an increased risk of psoriasis. Medical professionals should be aware of the potential adverse effects of immunotherapy to ensure optimal cancer care.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.4129","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T16:00:42Z","timestamp":1730908842000},"page":"31","source":"Crossref","is-referenced-by-count":15,"title":["Psoriasis Risk With Immune Checkpoint Inhibitors"],"prefix":"10.1001","volume":"161","author":[{"given":"Sheng-Yin","family":"To","sequence":"first","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsien","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lu","family":"Hsu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Shan","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Liang","family":"Wen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi240048r1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy.","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"doi240048r2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: a promising anticancer therapy.","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discov Today"},{"issue":"5","key":"doi240048r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"10","key":"doi240048r4","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"doi240048r5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity.","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"issue":"11","key":"doi240048r6","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease.","volume":"12","author":"Rakshit","year":"2020","journal-title":"J Thorac Dis"},{"key":"doi240048r7","doi-asserted-by":"publisher","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management.","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"doi240048r8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"doi240048r9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors.","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"doi240048r10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40257-020-00521-3","article-title":"Treatment goals in psoriasis: which outcomes matter most?","volume":"21","author":"Svoboda","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"doi240048r11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1468-3083.2010.03600.x","article-title":"Psoriasis: an epidemiological evaluation of disease burden in 590 patients.","volume":"24","author":"Meyer","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"19","key":"doi240048r12","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"doi240048r13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment.","volume":"45","author":"Ogawa","year":"2018","journal-title":"J Dermatol"},{"issue":"2","key":"doi240048r14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"doi240048r15","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7346030","article-title":"Activated circulating T follicular helper cells are associated with disease severity in patients with psoriasis.","volume":"2016","author":"Wang","year":"2016","journal-title":"J Immunol Res"},{"issue":"7","key":"doi240048r16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S2215-0366(24)00104-4","article-title":"Target trial emulation in psychiatry: a call for more rigorous observational analyses.","volume":"11","author":"Szmulewicz","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"doi240048r17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.7326\/M24-0004","article-title":"Benefits and risks associated with statin therapy for primary prevention in old and very old adults: real-world evidence from a target trial emulation study.","volume":"177","author":"Xu","year":"2024","journal-title":"Ann Intern Med"},{"issue":"9","key":"doi240048r18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","article-title":"Nationwide population science: lessons from the Taiwan National Health Insurance Research Database.","volume":"175","author":"Hsing","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"doi240048r19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jjco\/hyu211","article-title":"Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review.","volume":"45","author":"Chiang","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"doi240048r20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/pds.4267","article-title":"Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan.","volume":"27","author":"Kao","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"doi240048r21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/jjco\/hyq057","article-title":"Cancer trends in Taiwan.","volume":"40","author":"Chiang","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"doi240048r22","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"doi240048r23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"28","key":"doi240048r24","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"2","key":"doi240048r25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"1","key":"doi240048r26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research.","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"doi240048r27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.880985","article-title":"Persistence and adherence to biologics in patients with psoriasis in Taiwan: a new biologics user cohort study.","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"doi240048r28","doi-asserted-by":"publisher","DOI":"10.1177\/20406223231168488","article-title":"Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for psoriasis in Taiwan: a nationwide cohort followed from 2000 to 2017.","volume":"14","author":"Chiu","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"doi240048r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071108","article-title":"Target trial emulation: applying principles of randomised trials to observational studies.","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"issue":"14","key":"doi240048r30","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials.","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"doi240048r31","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi240048r32","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"issue":"36","key":"doi240048r33","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"doi240048r34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors.","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"doi240048r35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies.","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"issue":"3","key":"doi240048r36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2010.06.051","article-title":"The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.","volume":"65","author":"Balagula","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi240048r37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies.","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"doi240048r38","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2825850\/jamadermatology_to_2024_oi_240048_1736781522.57898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T16:01:19Z","timestamp":1736956879000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2825850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.4129","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}